Fox Business - The Power to Prosper
Search Site

Wednesday, April 7, 2010 as of 11:14 AM ET

Bristol-Myers Squibb

More Headlines »« Less Headlines
Bristol-Myers Squibb

Bristol-Myers Squibb (), often referred to as BMS, is a pharmaceutical company, headquartered in New York City.

Read More at Wikipedia ›

Related Topics

  1. Pfizer
  2. Gilead Sciences
  3. Amylin Pharmaceuticals
  4. Food And Drug Administration
  5. Eli Lilly
  6. Icahn Enterprises
Get updates on Bristol-Myers Squibb
FDA Panel Votes Against Expanded Approval Of Bayer, J&J's Xarelto

A Food and Drug Administration advisory panel narrowly voted against expanded use of Johnson & Johnson's (JNJ) and Bayer AG's (BAYRY, BAYN.

XE) anticlotting drug Xarelto to treat patients with a heart problem known as acute coronary syndrome because of concerns about life-threatening bleeding.Xarelto, considered part of a new generation of blood-thinning drugs, is already on the U.S. market and was approved last year to prevent strokes in patients with a heart rhythm disorder called atrial fibrillation, and is also approved for short-term use in patients undergoing knee- or hip-replacement surgery.The companies are now seeking approval to market Xarelto for use in treating acute coronary syndrome, which occurs when a blood clot develops inside a coronary artery and reduces blood flow to the heart. As part of that process, Xarelto was reviewed on Wednesday by an FDA advisory panel. The panel voted 6 to 4 against a question that asked whether Xarelto should be approved for the treatment o...

Read More ›

  1. Dow, NASDAQ, S&P 500 All in Green

    FBN's Nicole Petallides breaks down stocks boosting the Dow.

  2. Bristol -Myers 1Q Profit Beats Despite Generics

    Bristol-Myers Squibb (NYSE:BMY) reported a stronger-than-expected 10% increase in first-quarter profit, as strong demand for its melanoma and leukemia drugs helped s...

  3. Bristol -Myers 1Q Net Rises 12% On High Cancer Drug Sales

    Bristol-Myers Squibb Co. (BMY) reported a 12% increase in first-quarter profit, as rising sales of cancer drugs helped offset a decline in the company's top-selling ...

  4. Bristol-Myers Squibb Profit Climbs Above $1 Bln

    Bristol-Myers Squibb said Thursday its first-quarter profit climbed to $1.1 billion, or 64 cents a share, from $986 million, or 57 cents a share, in the year-ago per...

  5. Icahn: Suit Against Amylin Dropped After Talks With CEO

    DOW JONES NEWSWIRESActivist Investor Carl Icahn said he has dropped a lawsuit against Amylin Pharmaceuticals Inc. (AMLN) that sought to extend the drug maker's board...

  6. Icahn Drops Amylin Lawsuit

    Financier Carl Icahn said he has voluntarily dismissed a lawsuit filed against Amylin Pharmaceuticals Inc after talking with the biotech company's Chief Executive Of...

  7. UK Health Body Approves Novartis's Tasigna For CML

    The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-bas...

  8. Pfizer Earnings Could Get Boost On Nutrition Unit Sale

    Pfizer Inc.'s (PFE) earnings could get a boost in coming years if the drug maker uses most of the proceeds from the sale of its nutrition business for share buybacks...

  9. EU Body Backs AstraZeneca, Bristol's Diabetes Drug US Rejected

    Advisers to the European drug regulator recommended approval of an experimental diabetes drug that was rejected by U.S. regulators earlier this year amid concerns ab...

  10. Morgan Stanley, Bristol Myers Squibb Included in Stocks Up on High Volume Thursday

    Today, these stocks are up on high volume:Morgan Stanley (NYSE:MS) experienced a price hike on above-average volume today, trading at a volume of 49.6 million, or tw...

  11. WSJ BLOG/Health: A.M. Vitals: Human Genome Sciences Rejects Glaxo's $2.6 Billion Bid

    (This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.)Here's what's making health news this morning:Glaxo Bids ...

  12. Gilead, Bristol's Hepatitis C Drugs Show Promise In Study

    A regimen combining experimental drugs from Gilead Sciences Inc. (GILD) and Bristol-Myers Squibb Co. (BMY) suppressed the hepatitis C virus in most patients four wee...

  1. FDA Reviewer Backs Expanded Approval Of Bayer, J&J's Xarelto

    A Food and Drug Administration medical reviewer recommended the agency expand the approval of Johnson & Johnson's (JNJ) and Bayer AG's (BAYRY, BAYN.XE) anticlotting ...

  2. Amylin Climbs 6% On Buyout Speculation

    Shares of Amylin Pharmaceuticals climbed 6% in early trading Tuesday after analysts at Leerink Swann said they see Sanofi and Merck emerging as the strongest bidders...

  3. Teva 1Q Profit Up 13% On Branded, Generic Drug Sales

    Teva Pharmaceutical Industries Ltd. (TEVA) said Wednesday its first-quarter profit rose 13%, as sales growth for branded and generic drugs in the U.S. and emerging m...

  4. Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales

    Pfizer Inc.'s (PFE) first-quarter profit declined 19% as sales of its top product, the cholesterol-lowering drug Lipitor, tumbled 71% in the U.S. due to competition ...

  5. UPDATE: Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales

    ("UPDATE: Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales," published at 9:01 a.m. EDT, incorrectly stated sales for Prevnar 13 in the eleventh paragraph. A c...

  6. Expanding Probe Into Overseas Bribery

    FBN’s Liz MacDonald on the growing investigation into allegations of bribery overseas by U.S. companies.

  7. Health Care Sector Wrap

    On a trading day that saw the S&P 500 gain 0.7%, the Health Care sector (XLV) showed little change.Novacea (NASDAQ:TSPT) was a major loser in the sector, falling 15....

‹ Prev12345…Next ›
Freebase CC-BY
Source: Bristol-Myers Squibb on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL